Tags

Type your tag names separated by a space and hit enter

[Randomized, comparative study on the treatment of moderate arterial hypertension during pregnancy: methyldopa, acebutolol, labetalol].
Arch Mal Coeur Vaiss. 1988 Jun; 81 Spec No:137-40.AM

Abstract

The aim of this prospective, monocentric, opened study and with random order for antihypertensive sequence was to compare a betablocker with sympathomimetic activity (ACE) and an alphabetablocker (LAB) to the gold standard treatment (MD) in moderate HDP (BP greater than 90 mmHg). This study (January 1984 to December 1985) includes 63 women, mean age 28.2 years, divided into three comparable subgroups (age, parity, risk factors and initial level of SBP/DBP). Initial doses are 500 mg/bid (MD), and 400 mg/bid (ACE, LAB) and optimal dosages could not be respectively more than 1500 mg/bid (MD) or 1200 mg/bid (ACE, LAB). Usual criteria for maternal and foetal care are taken into account. The chi 2 test, the Student "t" test and the Kruskall Wallis test were used for statistical analysis. The results show: 1--A similar antihypertensive effect for MD and LAB, but significantly less for ACE (initial PAD-37th week PAD: MD +/- 18.8 +/- 2; LAB = -17.9 +/- 3; ACE = - 8.2 +/- 2.7 mmHg, p less than 0.02; 2--A more frequent adjustment of daily dosage with MD (n = 15) than with ACE (n = 10) or LAB (n = 7); 3--The absence of any significant difference for uricemia level, platelet counts, foetal cardiac rythm, and occurrence of pre-eclampsia (MD = 4; ACE = 3; LAB = 4; 4--An equivalent birth-weight (MD = 3110 +/- 628 g; ACE = 3115 +/- 645.(ABSTRACT TRUNCATED AT 250 WORDS)

Authors+Show Affiliations

Lardoux H
Service de cardiologie, hôpital Gilles-de-Corbeil, Corbeil-Essonnes.
Blazquez G
No affiliation info available
Leperlier E
No affiliation info available
Gérard J
No affiliation info available

MeSH

AcebutololAdultFemaleHeart Rate, FetalHumansHypertensionHypoglycemiaInfant, NewbornLabetalolMethyldopaPregnancyPregnancy Complications, CardiovascularProspective StudiesRandom Allocation

Pub Type(s)

Clinical Trial
Comparative Study
English Abstract
Journal Article
Randomized Controlled Trial

Language

fre

PubMed ID

3142396

Citation

Lardoux, H, et al. "[Randomized, Comparative Study On the Treatment of Moderate Arterial Hypertension During Pregnancy: Methyldopa, Acebutolol, Labetalol]." Archives Des Maladies Du Coeur Et Des Vaisseaux, vol. 81 Spec No, 1988, pp. 137-40.
Lardoux H, Blazquez G, Leperlier E, et al. [Randomized, comparative study on the treatment of moderate arterial hypertension during pregnancy: methyldopa, acebutolol, labetalol]. Arch Mal Coeur Vaiss. 1988;81 Spec No:137-40.
Lardoux, H., Blazquez, G., Leperlier, E., & Gérard, J. (1988). [Randomized, comparative study on the treatment of moderate arterial hypertension during pregnancy: methyldopa, acebutolol, labetalol]. Archives Des Maladies Du Coeur Et Des Vaisseaux, 81 Spec No, 137-40.
Lardoux H, et al. [Randomized, Comparative Study On the Treatment of Moderate Arterial Hypertension During Pregnancy: Methyldopa, Acebutolol, Labetalol]. Arch Mal Coeur Vaiss. 1988;81 Spec No:137-40. PubMed PMID: 3142396.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Randomized, comparative study on the treatment of moderate arterial hypertension during pregnancy: methyldopa, acebutolol, labetalol]. AU - Lardoux,H, AU - Blazquez,G, AU - Leperlier,E, AU - Gérard,J, PY - 1988/6/1/pubmed PY - 1988/6/1/medline PY - 1988/6/1/entrez SP - 137 EP - 40 JF - Archives des maladies du coeur et des vaisseaux JO - Arch Mal Coeur Vaiss VL - 81 Spec No N2 - The aim of this prospective, monocentric, opened study and with random order for antihypertensive sequence was to compare a betablocker with sympathomimetic activity (ACE) and an alphabetablocker (LAB) to the gold standard treatment (MD) in moderate HDP (BP greater than 90 mmHg). This study (January 1984 to December 1985) includes 63 women, mean age 28.2 years, divided into three comparable subgroups (age, parity, risk factors and initial level of SBP/DBP). Initial doses are 500 mg/bid (MD), and 400 mg/bid (ACE, LAB) and optimal dosages could not be respectively more than 1500 mg/bid (MD) or 1200 mg/bid (ACE, LAB). Usual criteria for maternal and foetal care are taken into account. The chi 2 test, the Student "t" test and the Kruskall Wallis test were used for statistical analysis. The results show: 1--A similar antihypertensive effect for MD and LAB, but significantly less for ACE (initial PAD-37th week PAD: MD +/- 18.8 +/- 2; LAB = -17.9 +/- 3; ACE = - 8.2 +/- 2.7 mmHg, p less than 0.02; 2--A more frequent adjustment of daily dosage with MD (n = 15) than with ACE (n = 10) or LAB (n = 7); 3--The absence of any significant difference for uricemia level, platelet counts, foetal cardiac rythm, and occurrence of pre-eclampsia (MD = 4; ACE = 3; LAB = 4; 4--An equivalent birth-weight (MD = 3110 +/- 628 g; ACE = 3115 +/- 645.(ABSTRACT TRUNCATED AT 250 WORDS) SN - 0003-9683 UR - https://www.unboundmedicine.com/medline/citation/3142396/[Randomized_comparative_study_on_the_treatment_of_moderate_arterial_hypertension_during_pregnancy:_methyldopa_acebutolol_labetalol]_ DB - PRIME DP - Unbound Medicine ER -